Ylenia Ferrara

Dr. Ylenia Ferrara

Institute of Biostructures and Bioimaging, CNR Italian National Research Council, Rome, Lazio, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAnnachiara Sarnella
Annachiara Sarnella
YFYlenia Ferrara
Ylenia Ferrara
CTCristina Terlizzi
Cristina Terlizzi
SASandra Albanese
Sandra Albanese
Serena MontiSerena Monti
Serena Monti
MMMarcello Mancini
Marcello Mancini
The chicken embryo has emerged as a valuable model for preclinical studies due to its unique combination of accessibility, affordability, and relevance to human biology. Its rapid development, external growth environment, and clear structural visibility offer distinct advantages over traditional mammalian models. These features facilitate the study of real-time biological processes, including tissue development, tumor growth, angiogenesis, and drug delivery, using various imaging modalities, such as optical imaging, magnetic resonance imaging, positron emission tomography, computed tomography, and ultrasound. The chicken embryo model also minimizes ethical concerns compared to mammalian models, as it allows for early-stage research without the complexity of a fully developed animal. Moreover, its ability to integrate human tumor cells into xenograft models provides a reliable platform for cancer research, enabling high-throughput screening of therapeutic interventions and tracking molecular dynamics in vivo. Advances in molecular imaging techniques further enhance the resolution and depth of data obtained from these studies, offering insights into cellular and molecular mechanisms underlying disease. Given its versatility, cost-effectiveness, and translational potential, the chicken embryo represents a promising tool for advancing preclinical research, particularly in drug development, cancer biology, and regenerative medicine.

20 May 2026 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
YFYlenia Ferrara
Ylenia Ferrara
CTCristina Terlizzi
Cristina Terlizzi
ASAnnachiara Sarnella
Annachiara Sarnella
LLLuca Licenziato
Luca Licenziato
Serena MontiSerena Monti
Serena Monti
MMMarcello Mancini
Marcello Mancini
Preclinical multimodal imaging is widely applied in small animal models for longitudinal studies of human diseases. Beyond murine systems, cost-effective and ethically sustainable models such as the chicken embryo and its chorioallantoic membrane are gaining increasing interest in accordance with the 3Rs principles. This study evaluated the feasibility of using both high-frequency ultrasound and magnetic resonance imaging for the non-invasive longitudinal monitoring of chicken embryo development in ovo. Fifty fertilized eggs were incubated under controlled conditions and examined up to embryonic day 14. High-frequency ultrasound (15–71 MHz) enabled real-time imaging and quantitative assessment of superficial structures, including cranial biometry and limb growth, while magnetic resonance imaging (7T) provided high-resolution three-dimensional visualization of internal organs and extraembryonic compartments. Together, these modalities allowed the progressive identification of key anatomical structures from ED5 onward, with HFUS enabling earlier linear measurements and MRI facilitating detailed anatomical and volumetric evaluation. The integration of these techniques allowed the generation of a developmental imaging timeline and quantitative reference dataset of normal embryogenesis. This multimodal approach represents a promising strategy for in vivo developmental studies, offering a robust baseline to characterize structural alterations induced by experimental conditions. Moreover, the use of the chicken embryo model provides significant ethical and economic advantages, supporting its application in preclinical research and imaging-based studies.

31 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CTCristina Terlizzi
Cristina Terlizzi
YFYlenia Ferrara
Ylenia Ferrara
ASAnnachiara Sarnella
Annachiara Sarnella
Breast cancer is a highly heterogeneous disease characterized by distinct molecular subtypes, dynamic tumor–microenvironment interactions, and variable therapeutic responses. Despite the availability of multiple preclinical platforms, a major challenge remains the lack of a coherent multiscale framework capable of integrating biological complexity across experimental systems. This limitation reduces the predictive power of individual models and highlights the need for complementary strategies that reproduce disease progression across multiple biological scales. In this context, advanced imaging technologies have emerged as essential tools for linking preclinical platforms and enhancing their translational relevance. This review examines how multimodal imaging supports the integration of in vitro, ex vivo, and in vivo breast cancer models. We discuss how optical imaging, high-frequency ultrasound, magnetic resonance imaging, positron emission tomography/computed tomography, and intravital microscopy provide complementary molecular, functional, anatomical, and cellular information for the longitudinal assessment of tumor growth, metastatic dissemination, microenvironment remodeling, and therapeutic response. Particular attention is given to emerging translational workflows that combine patient-derived models with advanced imaging to investigate drug sensitivity, treatment resistance, and tumor progression within a precision oncology perspective. We also highlight the role of multimodal imaging in biomarker validation across platforms and in the development of clinically relevant preclinical pipelines. Overall, advanced imaging represents a critical translational bridge across breast cancer model systems, improving the predictive value of preclinical studies and supporting imaging-guided precision oncology from bench to bedside.